ArriVent BioPharma, Inc. (AVBP) vs Collegium Pharmaceutical, Inc. (COLL)
A side-by-side comparison of ArriVent BioPharma, Inc. and Collegium Pharmaceutical, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.42HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
COLL
Collegium Pharmaceutical, Inc.
$22.03HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — AVBP vs COLL
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)COLL -34.0% (-12.9%/yr)AVBP compounded faster over this window
AVBP COLL
AVBP vs COLL: by the numbers
- •AVBP is the larger company ($718M vs $715M market cap).
- •COLL is profitable (5.93% net margin) while AVBP runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AVBP | COLL |
|---|---|---|
| P/E ratio | N/A | 17.77 |
| PEG ratio | N/A | 0.99 |
| P/S ratio | N/A | 0.88 |
| P/B ratio | 1.96 | 2.29 |
| EV / EBITDA | N/A | 2.85 |
| FCF yield | N/A | 45.94% |
Profitability
| Metric | AVBP | COLL |
|---|---|---|
| Gross margin | 0.00% | 60.02% |
| Operating margin | 0.00% | 19.61% |
| Net margin | 0.00% | 5.93% |
| ROE | -44.63% | 15.36% |
| ROIC | -47.96% | 6.11% |
Growth (annualized)
| Metric | AVBP | COLL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 19.91% |
| EPS CAGR (5Y) | N/A | 20.48% |
| FCF CAGR (5Y) | N/A | 26.38% |
| Total return CAGR (5Y) | N/A | 2.15% |
Frequently asked
- Is AVBP or COLL more profitable?
- COLL runs the higher net margin — AVBP at 0.00% versus COLL at 5.93%.
Go deeper
Dig into the metrics
Collegium Pharmaceutical P/E ratioArriVent BioPharma ROECollegium Pharmaceutical ROEArriVent BioPharma operating marginCollegium Pharmaceutical operating marginArriVent BioPharma revenue growthCollegium Pharmaceutical revenue growthArriVent BioPharma free cash flowCollegium Pharmaceutical free cash flow
ArriVent BioPharma & Collegium Pharmaceutical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.